HB 1617 creates new sections in Florida law governing stem cell therapy performed by licensed allopathic and osteopathic physicians. The bill authorizes physicians to provide certain stem cell therapies that have not been approved by the U.S. Food and Drug Administration, but only when the treatment is within the physician’s scope of practice and limited to orthopedics, wound care, or pain management. It also defines key terms, including what counts as stem cell therapy and what types of human cells, tissues, or cellular or tissue-based products are covered or excluded.
The bill sets detailed conditions for the stem cells that may be used. Those cells must be manufactured in FDA-certified clean-room conditions, retrieved/manufactured/stored in properly registered and accredited facilities, and accompanied by post-thaw viability analysis showing live cells. Physicians are barred from obtaining stem cells from facilities lacking the required accreditation or certification, and contracts with those facilities must include disclosure and notice provisions about certification status.
HB 1617 also imposes patient-protection and advertising requirements. Physicians must include a conspicuous warning in any advertisement stating that the therapy is not FDA-approved and encouraging consultation with a primary care provider. Before treatment, the physician must obtain a signed informed-consent form that explains the nature of the treatment, its unapproved status, expected results, risks, benefits, alternatives, and the recommendation to consult a primary care provider. The bill excludes FDA-approved investigational new drug or device uses and certain therapies performed under certified institutions.
The bill’s impact on state law is to create a regulatory framework for non-FDA-approved stem cell therapies in Florida, while limiting the practice to specific physician types and medical uses and tying it to federal manufacturing standards and accreditation systems. It also authorizes disciplinary action for violations and directs the Board of Medicine and the Board of Osteopathic Medicine to adopt implementing rules. The act would take effect July 1, 2025.
The overall sentiment reflected in the bill text is supportive of stem cell innovation but cautious and restrictive, emphasizing ethical sourcing, patient disclosure, and quality controls. No committee transcripts or recorded votes were provided, so there is no additional evidence of debate or opposition in the supplied materials. The available context suggests the bill moved in tandem with a companion measure that passed, while HB 1617 itself was laid on the table.
HB 1617 would add new statutory provisions to chapters governing medical practice for both allopathic and osteopathic physicians, creating a regulated pathway for certain non-FDA-approved stem cell therapies. It would impose sourcing, manufacturing, accreditation, advertising, consent, and record/contract requirements, and expose physicians to board discipline for noncompliance. It also requires rulemaking by the relevant professional boards and takes effect July 1, 2025.
The bill’s tone is generally favorable toward stem cell therapy as a medical innovation, but it is framed with strong ethical and safety guardrails. Because no committee discussion or vote record was provided, there is no documented floor or committee sentiment to assess beyond the bill’s own language and the note that a companion bill passed while HB 1617 was laid on the table.
The main policy tension in the bill is between expanding access to stem cell therapies and restricting them to ethically sourced, tightly regulated products. The bill expressly excludes fetal-derived stem cells and therapies involving tissue from abortions, which may reflect a major value-based point of contention. It also limits use to certain specialties and conditions, requires FDA-linked manufacturing and accreditation standards, and mandates prominent advertising warnings and informed consent, all of which suggest concern about unproven treatments and patient protection. No specific stakeholder objections or support were included in the provided transcripts.